CA 125 in gynecological pathology — a review

Kenemans, P.; Yedema, C.A.; Bon, G.G.; Mensdorff‐Pouilly, Silvia von

doi:10.1016/0028-2243(93)90135-y

Cited by 80 publications

(47 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The withinassay coefficient of variation (CV) was 6.6% (n ¼ 60), whereas the between-assay CV was 6.2% (n ¼ 10) at a control sample of 30 U ml À1 . Cancer antigen 125 levels below 35 U ml À1 were considered as normal in agreement with the literature (Bast et al, 1983;Kenemans et al, 1993;Markman, 1994), and were regardless of the exact CA125 result changed to o35 U ml À1 .…”

Section: Ca125 Assaysupporting

confidence: 63%

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

et al. 2004

View full text Add to dashboard Cite

Recent studies indicate that cancer antigen 125 (CA125) response criteria tend to overestimate a tumour reduction measured by standard WHO response criteria in recurrent epithelial ovarian carcinoma. The aim of the study was to validate the recently introduced GCIG (The Gynaecological Cancer Intergroup) CA125 response criteria in predicting a tumour response measured by WHO (World Health Organization) criteria. Changes in CA125 levels (GCIG criteria) were retrospectively compared with alterations in the tumour load (WHO criteria) during second-line chemotherapy with topotecan or paclitaxel -platinum in 124 consecutive patients with recurrent or refractory disease. In patients assessable by both response criteria (n ¼ 72), the overall response rate using GCIG CA125 criteria was 57% (95% confidence interval (CI): 45 -69%) and significantly higher than the response rate of 39% (95% CI: 28 -51%) using WHO response criteria (P ¼ 0.045). The GCIG CA125 criteria had a sensitivity of 96% (95% CI: 82 -100%), a specificity of 68% (95% CI: 52 -81%) and an accuracy of 79% (95% CI: 68 -88%) in predicting a response measured by WHO criteria. In conclusion, the GCIG CA125 response criteria seem to overestimate a tumour response by WHO criteria when monitoring the efficacy of second-line chemotherapy with topotecan or paclitaxel -platinum in patients with epithelial ovarian carcinoma.

show abstract

Section: Ca125 Assaysupporting

confidence: 63%

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Moreover, even when surgical resection specimens are evaluated, immunostains are still used in conjunction with histomorphology to confirm a diagnosis, particularly when a rare entity such as SVCA is entertained. CA-125 is a large, highly glycosylated glycoprotein that is found in the epithelium of the fallopian tubes, endometrium, cervix, pleura, peritoneum, and pericardium (10,11). More than 80% of female genital tract neoplasms demonstrate CA-125 immunoreactivity, including serous, mucinous, endometrioid, and clear cell carcinomas (10 -12).…”

Section: Discussionmentioning

confidence: 99%

Primary Seminal Vesicle Carcinoma: An Immunohistochemical Analysis of Four Cases

et al. 2000

View full text Add to dashboard Cite

Primary adenocarcinoma of the seminal vesicles is an extremely rare neoplasm. Because prompt diagnosis and treatment are associated with improved long-term survival, accurate recognition of this neoplasm is important, particularly when evaluating limited biopsy material. Immunohistochemistry can be used to rule out neoplasms that commonly invade the seminal vesicles, such as prostatic adenocarcinoma. Previous reports have shown that seminal vesicle adenocarcinoma (SVCA) is negative for prostate-specific antigen (PSA) and prostatespecific acid phosphatase (PAP); however, little else is known of its immunophenotype. Consequently, we evaluated the utility of cancer antigen 125 (CA-125) and cytokeratin (CK) subsets 7 and 20 for distinguishing SVCA from other neoplasms that enter the differential diagnosis.Four cases of SVCA-three cases of bladder adenocarcinoma and a rare case of adenocarcinoma arising in a mullerian duct cyst-were immunostained for CA-125, CK7, and CK20. Three of four cases of SVCA were CA-125 positive and CK7 positive. All four cases were CK20 negative. All bladder adenocarcinomas and the mullerian duct cyst adenocarcinoma were CK7 positive and negative for CA-125 and CK20. In addition, CA-125 immunostaining was performed in neoplasms that commonly invade the seminal vesicles, including prostatic adenocarcinoma (n ‫؍‬ 40), bladder transitional cell carcinoma (n ‫؍‬ 32), and rectal adenocarcinoma (n ‫؍‬ 10), and all were negative for this antigen.In conclusion, the present study has shown that the CK7-positive, CK20-negative, CA-125-positive, PSA/PAP-negative immunophenotype of papillary SVCA is unique and can be used in conjunction with histomorphology to distinguish it from other tumors that enter the differential diagnosis, including

show abstract

“…The CA125 antigen became an established marker, nowadays commonly used in gynaecological practice for management of patients with ovarian cancer. 2,3 In the original Centocor CA125 assay (Fujirebio Diagnostics, Malvern, USA), a homologous doubledeterminant assay, the OC125 MAb was used both as capture and tracer antibody. Therefore, repetition of the antibody-de¢ned epitope on the CA125 antigen is mandatory for binding and detection.…”

Section: Introductionmentioning

confidence: 99%

Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays

et al. 2003

View full text Add to dashboard Cite

show abstract

CA 125 in gynecological pathology — a review

Cited by 80 publications

References 8 publications

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

Primary Seminal Vesicle Carcinoma: An Immunohistochemical Analysis of Four Cases

Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays

Contact Info

Product

Resources

About